While investors chase semiconductor stocks, the healthcare sector has been sold down to historic lows relative to the S&P 500. Companies like Intuitive Surgical possess unique, valuable proprietary data that AI will leverage, turning these unloved firms into a compelling, long-term AI play.

The strong performance of biotech stocks in late 2025 wasn't solely driven by sector-specific news. A significant factor was a macro-level rotation of capital from generalist investors moving money out of cooling AI and tech stocks and into the undervalued healthcare and biotech sectors.

A key driver for renewed interest in European equities is not just a search for value, but a strategic move to hedge against volatility in the US AI sector. Investors, while maintaining their AI holdings, are allocating new capital to Europe to diversify and mitigate risk from the AI complex's price swings.

Navigate AI's uncertainty with a two-sided "barbell" approach. On one end, make high-risk bets on "AI-first" businesses. On the other, invest in stable industries AI won't eliminate, such as healthcare, food, and entertainment, which cater to timeless human needs.

Beyond the crowded AI trade, smart money sees opportunity in overlooked sectors. These include healthcare, which is at a 30-year low in relative valuation, and companies serving the middle-income consumer, a segment poised to benefit from upcoming tax reforms.

Contrary to its volatile reputation, the XBI biotech index has been relatively stable. Its recent underperformance compared to the S&P 500 is not due to weakness in biotech, but rather the S&P's own AI-fueled volatility, which created a temporary outperformance that has since corrected.

Generalist investors are expanding their focus beyond a few large-cap momentum stocks like Eli Lilly. Their growing interest in a wider range of pharma companies signals a defensive shift away from an expensive S&P 500 and AI trade into the relatively undervalued biotech sector.

Fears that AI will render software and other tech industries obsolete are driving a significant capital shift. Investors are selling tech stocks and buying into sectors perceived as immune to AI disruption, such as energy, construction, and consumer staples. This rotation explains the recent underperformance of tech-heavy indices.

When a few high-flying stocks like the 'Mag-7' dominate the market, capital is pulled from other sectors, creating cyclical valuation discounts. Stable industries like healthcare can become as cheap relative to the S&P 500 as they were during the 2000 tech bubble, presenting a contrarian investment opportunity.